5-Amino-1MQ Human Clinical Trials: 2026 Status and Fat Loss Mechanism

What 5-Amino-1MQ Is

5-Amino-1-methylquinolinium iodide (5-amino-1MQ) is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT). Despite appearing in peptide-focused clinical practice discussions, 5-amino-1MQ is not a peptide — it is a small molecule. Its inclusion in metabolic-medicine conversation reflects the growing willingness of physicians to consider mechanism-first compounds across classes.

NNMT is an enzyme that methylates nicotinamide, consuming S-adenosylmethionine (SAM) in the process. NNMT overexpression has been associated with metabolic dysfunction, obesity, and reduced NAD+ availability. Inhibiting NNMT has been proposed as a therapeutic strategy for metabolic disease.

The Fat Loss Mechanism

The proposed fat loss mechanism of 5-amino-1MQ operates through several interrelated effects:

• NNMT inhibition preserves SAM and NAD+ pools
• Increased NAD+ supports sirtuin activity and mitochondrial function
• Reduced lipogenesis — adipocyte fatty acid synthesis is decreased
• Enhanced adipocyte metabolism — improved adipose tissue function
• Selective effect on adipocytes — relative sparing of other tissues

Preclinical studies have shown that 5-amino-1MQ treatment in mice produces:

• Reduced body fat mass
• Improved insulin sensitivity
• Preserved lean mass
• Favorable effects on liver fat in diet-induced obesity models

The Human Clinical Trials Picture

As of 2026, human clinical trial activity for 5-amino-1MQ is emerging but not yet mature. Key features of the current landscape:

• Academic and biotech interest has advanced the compound from early preclinical to translational work

• Phase 1 human trials have been registered in some geographies
• Published human efficacy data at the level of a completed, results-reported phase 2 study are not yet a settled part of the dataset
• Commercial development is active but has not produced a near-term approval path

Patients and clinicians tracking 5-amino-1MQ should monitor ClinicalTrials.gov and peer-reviewed publications for current status.

Why Compounding Access Is Not an Established Path

5-amino-1MQ is not on the FDA 503A bulk drug substances list. It is a research compound being developed through the conventional drug development pathway — not a compounding-pharmacy-accessible substance. Patients encountering 5-amino-1MQ outside of proper clinical trial enrollment are typically accessing research-grade material from non-clinical sources, which is not an appropriate pathway for physician-supervised use.

Positioning in the Metabolic Medicine Conversation

For physicians fielding patient questions about 5-amino-1MQ, the appropriate framing:

• Promising mechanism with solid preclinical rationale
• Early clinical development — human efficacy and safety not yet well characterized
• No legitimate clinical access pathway in the United States as of 2026
• Alternative evidence-based options exist for the underlying metabolic optimization goals patients typically pursue

Key Takeaways

• 5-amino-1MQ is a small-molecule NNMT inhibitor, not a peptide.
• The proposed fat loss mechanism operates through SAM and NAD+ preservation.
• Preclinical data support fat loss and metabolic benefits.
• Human clinical trial activity is emerging; completed efficacy trials are not yet established.
• There is no legitimate compounding or clinical access pathway in U.S. practice.
• Patients should be directed toward evidence-based alternatives for metabolic optimization.

Frequently Asked Questions

Has 5-amino-1MQ been tested in humans?

Human clinical trial activity is emerging but limited. Published human efficacy data are not yet mature.

How does 5-amino-1MQ reduce fat?

By inhibiting NNMT, which preserves SAM and NAD+ pools, supports sirtuin activity, and reduces adipocyte lipogenesis.

Can I get 5-amino-1MQ through a compounding pharmacy?

No. It is not on the FDA 503A bulk drug substances list.

Is 5-amino-1MQ safe?

Preclinical data have not shown prominent adverse effects, but human safety data are limited.